Interventions: Drug: KK-LC-1 TCR-T cells; Drug: Aldesleukin 720,000 IU/kg IV every eight hours
Sponsors: Christian Hinrichs; Cancer Immunology and Metabolism Center of Excellence at Rutgers Cancer Institute of New Jersey; T Cure Bioscience; National Cancer Institute (NCI)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.